FORIMTAMIG, A GPRC5DXCD3 BISPECIFIC ANTIBODY, SHOWS PROMISING ACTIVITY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS FROM A PHASE I STUDY INVESTIGATING IV AND SC DOSING

MODAKAFUSP ALFA: FINAL RESULTS FROM THE FIRST-IN-HUMAN PHASE 1/2 IINNOVATE-1 STUDY OF AN INNATE IMMUNITY ENHANCER IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Efficacy Results, Ocular Adverse Events and Functional Impact in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin plus Lenalidomide/ Dexamethasone in the Phase 1/2 BelaRd Study

SINGLE-AGENT BELANTAMAB MAFODOTIN (BELAMAF) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL ANALYSIS OF THE DREAMM-2 TRIAL

IN-CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA BY AGE AND FRAILTY STATUS: UPDATED SUBGROUP ANALYSES FROM THE FULLY ACCRUED US MM-6 COHORT

SAFETY AND EFFICACY OF LINVOSELTAMAB (REGN5458), A BCMAXCD3 BISPECIFIC ANTIBODY TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PHASE 1/2 FIRST-IN-HUMAN STUDY

CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP

MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 1/2 RESULTS FROM MONUMENTAL-1

TECLISTAMAB IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB AND LENALIDOMIDE IN PATIENTS WITH MULTIPLE MYELOMA: RESULTS FROM ONE COHORT OF MAJESTEC-2, A PHASE 1B, MULTICOHORT STUDY

DVRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VERSUS DVRD FOLLOWED BY ASCT IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE TRANSPLANT ELIGIBLE: A RANDOMIZED PHASE 3 STUDY (EMAGINE/CARTITUDE-6)

HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY: PATIENT-REPORTED OUTCOMES FROM MONUMENTAL-1

NO EVIDENCE OF B-CELL MATURATION ANTIGEN EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

THE IINNOVATE CLINICAL DEVELOPMENT PROGRAM: RATIONALE AND DESIGN OF ONGOING PHASE 1/2 TRIALS OF MODAKAFUSP ALFA, AN INNATE IMMUNITY ENHANCER, IN PATIENTS WITH MULTIPLE MYELOMA